HIV vaccines based on neutralising antibody and CD8 cyto- Post hoc analysis of the RV144 trial indicated that IgG binding antibodies directed at the V1-V2 region of the HIV envelope were associated with protection 7
HIV vaccines based on neutralising antibody and CD8 cytotoxic T-cell immunity have failed to induce protection in phase III clinical trials, while live attenuated HIV vaccines (although effective in simian models) are considered too dangerous to use in humans due to reversion to virulence.
New strategies and lateral thinking are required to develop a safe and effective vaccine against HIV. Antibody dependent cellular cytotoxicity (ADCC) represents one such modality that provides potential advantages over previous modalities and may also have a role in efforts to cure HIV infection.
As of December 2012, the WHO and UNAIDS estimated that 35 million people were infected with HIV and while anti-retroviral medication (ARV) has greatly improved the health of these individuals, only 9.7 million people are actually on ARV therapy To date, only the Thai RV144 vaccine trial has shown any efficacy in preventing HIV acquisition (31% reduction; P = 0.04) 3 . Vaccines In recent years our group has described a method of (a) identifying which HIV-infected subjects display HIV-specific ADCC, (b) quantifying the magnitude and cytokine profile of the response and (c) defining the exact antigenic target of the response 11 . although such responses are (like neutralising antibody and CD8
T-cell responses) subject to immune escape 14 .
The ability of ADCC to target highly conserved internal HIV proteins (such as integrase 12 ) is very attractive in a preventive vaccine strategy, although it remains unclear how these antigens are expressed by virus-infected cells. In terms of a therapeutic vaccine modality, HIV-specific ADCC has other potential advantages including the ability to target virus-infected cells (rather than free virions), the fact that ADCC is not restricted by HLA phenotype and ADCC can act at mucosal sites rather than in regional lymph nodes. We are proposing trialling passive vaccines strategies in macaques to evaluate the preventive efficacy of HIV-specific ADCC. HIV-specific ADCC was induced in the partially effective RV144 trial and correlated with reduced risk of infection 7 . The ability to induce effective ADCC antibodies by vaccination may be due to a reduced need for somatic mutation of immunoglobulin chains, compared to the hypermutation described for broadly effective neutralising antibodies 15 We have also recently proposed a speculative but as yet untested additional role for HIV-specific ADCC, as part of efforts to cure HIV infection 16 . Researchers have sought ways to induce cells latently infected with HIV to express viral antigens and then use the immune system to clear the viral reservoir and effect a cure 17 . ADCC antibodies are potentially an attractive vehicle to promote clearance of latently infected cells, as an alternative to previously described (but ineffective) cytotoxic T-cell responses 18 .
In summary, ADCC antibodies to both Envelope and conserved internal proteins of HIV are attractive immune responses to induce by vaccination and may be able to improve upon the success of the Thai RV144 trial. Future research in my lab over the coming years will aim to isolate, purify and test the preventive and therapeutic potential of HIV-specific ADCC antibodies.
